Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Fields, Jerel A ^a   Overk, Cassia ^b   Adame, Anthony ^b   Florio, Jazmin ^b   Mante, Michael ^b   Pineda, Andrea ^b   Desplats, Paula ^b   Rockenstein, Edward ^b   Achim, Cristian ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FK506; Gp120; HIV; Neuro inflammation

Indexed keywords

CALCIUM; GLYCOPROTEIN GP 120; INTERLEUKIN 6; MITOFUSIN 1; TACROLIMUS; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN MITOCHONDRION; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; GLIOSIS; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERACTIVITY; MOUSE; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; ANALYSIS OF VARIANCE; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; MITOCHONDRION; NERVE DEGENERATION; NEUROTOXICITY SYNDROMES; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HIV ENVELOPE PROTEIN GP120; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MICE; MICROFILAMENT PROTEINS; MITOCHONDRIA; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROTOXICITY SYNDROMES; TACROLIMUS; TACROLIMUS BINDING PROTEINS; TREATMENT OUTCOME;

EID: 84973345094     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0585-8     Document Type: Article

References (65)

1. Potula R, Dhillion N, Sui Y, Zien CA, Funa K, Pinson D, et al. Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis. Am J Pathol. 2004;165:815-24.
2. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013;13:976-86.
3. Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS. 2011;22:608-9.
4. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33-44.
5. Crews L, Patrick C, Achim CL, Everall IP, Masliah E. Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci. 2009;10:1045-63.
6. Etherton MR, Lyons JL, Ard KL. HIV-associated neurocognitive disorders and antiretroviral therapy: current concepts and controversies. Curr Infect Dis Rep. 2015;17:485.
7. Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res. 2012;21:79-89.
8. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24:275-83.
9. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988-94.
10. Lipton SA. AIDS-related dementia and calcium homeostasis. Ann N Y Acad Sci. 1994;747:205-24.
11. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol. 2000;47:186-94.
12. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-22.
13. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 2005;19:127-35.
14. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186 Suppl 2:S193-8.
15. Norman JP, Perry SW, Reynolds HM, Kiebala M, De Mesy Bentley KL, Trejo M, et al. HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One. 2008;3:e3731.
16. Fields J, Dumaop W, Eleuteri S, Campos S, Serger E, Trejo M, et al. HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders. J Neurosci. 2015;35:1921-38.
17. Alirezaei M, Kiosses WB, Fox HS. Decreased neuronal autophagy in HIV dementia: a mechanism of indirect neurotoxicity. Autophagy. 2008;4:963-6.
18. Campbell GR, Rawat P, Bruckman RS, Spector SA. Human immunodeficiency virus type 1 Nef inhibits autophagy through transcription factor EB sequestration. PLoS Pathog. 2015;11:e1005018.
19. Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, et al. Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol. 2011;178:1646-61.
20. Kehn-Hall K, Guendel I, Carpio L, Skaltsounis L, Meijer L, Al-Harthi L, et al. Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology. 2011;415:56-68.
21. Fields JA, Serger E, Campos S, Divakaruni AS, Kim C, Smith K, et al. HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiol Dis. 2016;86:154-69.
22. Valcour V, Shiramizu B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion. 2004;4:119-29.
23. Chattopadhaya S, Harikishore A, Yoon HS. Role of FK506 binding proteins in neurodegenerative disorders. Curr Med Chem. 2011;18:5380-97.
24. Cao W, Konsolaki M. FKBP immunophilins and Alzheimer's disease: a chaperoned affair. J Biosci. 2011;36:493-8.
25. Rosenstock TR, de Brito OM, Lombardi V, Louros S, Ribeiro M, Almeida S, et al. FK506 ameliorates cell death features in Huntington's disease striatal cell models. Neurochem Int. 2011;59:600-9.
26. Uittenbogaard M, Chiaramello A. Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des. 2014;20:5574-93.
27. Dickey AS, Strack S. PKA/AKAP1 and PP2A/Bbeta2 regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics. J Neurosci. 2011;31:15716-26.
28. Berthet A, Margolis EB, Zhang J, Hsieh I, Hnasko TS, Ahmad J, et al. Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. J Neurosci. 2014;34:14304-17.
29. Guo X, Macleod GT, Wellington A, Hu F, Panchumarthi S, Schoenfield M, et al. The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. Neuron. 2005;47:379-93.
30. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol. 2003;160:1115-27.
31. Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol. 2011;13:589-98.
32. Scorrano L. Keeping mitochondria in shape: a matter of life and death. Eur J Clin Invest. 2013;43:886-93.
33. Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci. 2010;67:3435-47.
34. Bertholet AM, Delerue T, Millet AM, Moulis MF, David C, Daloyau M, et al. Mitochondrial fusion/fission dynamics in neurodegeneration and neuronal plasticity. Neurobiol Dis. 2016;90:3-19. doi: 10.1016/j.nbd.2015.10.011. Epub 2015 Oct 19.
35. Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem. 2003;3:1376-82.
36. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-42.
37. Yokoyama T, Tanoue T, Hasegawa E, Ikeda Y, Ohta S, Omi A, et al. Evaluation of the protective effects of cyclosporin a and FK506 on abnormal cytosolic and mitochondrial Ca(2)(+) dynamics during ischemia and exposure to high glutamate concentration in mouse brain slice preparations. J Pharmacol Sci. 2012;120:228-40.
38. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695-7.
39. Sanchez-Perez I, Rodriguez-Hernandez CJ, Manguan-Garcia C, Torres A, Perona R, Murguia JR. FK506 sensitizes mammalian cells to high osmolarity by modulating p38 MAP kinase activation. Cell Mol Life Sci. 2004;61:700-8.
40. Aomatsu T, Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Yoden A, et al. Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts. Int J Mol Med. 2012;30:1152-8.
41. Klettner A, Herdegen T. FK506 and its analogs-therapeutic potential for neurological disorders. Curr Drug Targets CNS Neurol Disord. 2003;2:153-62.
42. Overk CR, Rockenstein E, Florio J, Cheng Q, Masliah E. Differential calcium alterations in animal models of neurodegenerative disease: reversal by FK506. Neuroscience. 2015;310:549-60.
43. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994;367:188-93.
44. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One. 2010;5:e9313.
45. Devor A, Tian P, Nishimura N, Teng IC, Hillman EM, Narayanan SN, et al. Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygenation level-dependent signal. J Neurosci. 2007;27:4452-9.
46. Stosiek C, Garaschuk O, Holthoff K, Konnerth A. In vivo two-photon calcium imaging of neuronal networks. Proc Natl Acad Sci U S A. 2003;100:7319-24.
47. Mucke L, Abraham C, Ruppe M, Rockenstein E, Toggas S, Alford M, et al. Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP). J Exp Med. 1995;181:1551-6.
48. Overk CR, Cartier A, Shaked G, Rockenstein E, Ubhi K, Spencer B, et al. Hippocampal neuronal cells that accumulate alpha-synuclein fragments are more vulnerable to Abeta oligomer toxicity via mGluR5-implications for dementia with Lewy bodies. Mol Neurodegener. 2014;9:18.
49. Reznichenko L, Cheng Q, Nizar K, Gratiy SL, Saisan PA, Rockenstein EM, et al. In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy. J Neurosci. 2012;32:9992-8.
50. Aghdasi B, Ye K, Resnick A, Huang A, Ha HC, Guo X, et al. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acad Sci U S A. 2001;98:2425-30.
51. Henry BL, Geyer MA, Buell M, Perry W, Young JW, Minassian A. Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav Brain Res. 2013;236:210-20.
52. Gaali S, Gopalakrishnan R, Wang Y, Kozany C, Hausch F. The chemical biology of immunophilin ligands. Curr Med Chem. 2011;18:5355-79.
53. Zawadzka M, Kaminska B. A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia. 2005;49:36-51.
54. Saganova K, Galik J, Blasko J, Korimova A, Racekova E, Vanicky I. Immunosuppressant FK506: focusing on neuroprotective effects following brain and spinal cord injury. Life Sci. 2012;91:77-82.
55. Gerard M, Deleersnijder A, Daniels V, Schreurs S, Munck S, Reumers V, et al. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J Neurosci. 2010;30:2454-63.
56. Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, et al. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an alpha-synuclein-based rat model for Parkinson's disease. Neurobiol Aging. 2015;36:1559-68.
57. Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol. 2003;53:57-64.
58. Soontornniyomkij V, Risbrough VB, Young JW, Wallace CK, Soontornniyomkij B, Jeste DV, et al. Short-term recognition memory impairment is associated with decreased expression of FK506 binding protein 51 in the aged mouse brain. Age (Dordr). 2010;32:309-22.
59. Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses. J Cell Mol Med. 2004;8:45-58.
60. Nakagaki T, Satoh K, Ishibashi D, Fuse T, Sano K, Kamatari YO, et al. FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice. Autophagy. 2013;9:1386-94.
61. Fields J, Dumaop W, Adame A, Ellis RJ, Letendre S, Grant I, et al. Alterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol. 2013;8:1197-209.
62. Kahraman S, Bambrick LL, Fiskum G. Effects of FK506 and cyclosporin a on calcium ionophore-induced mitochondrial depolarization and cytosolic calcium in astrocytes and neurons. J Neurosci Res. 2011;89:1973-8.
63. Almeida S, Domingues A, Rodrigues L, Oliveira CR, Rego AC. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol Dis. 2004;17:435-44.
64. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338.
65. Neuspiel M, Zunino R, Gangaraju S, Rippstein P, McBride H. Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization. J Biol Chem. 2005;280:25060-70.